Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2026
Angiopoietins and Angiopoietin-Like Proteins as New Biomarkers in Posttransplant Diabetes Mellitus: A Single-Center Study From Kuwait.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jahromi Mohamed, Al-Otaibi Torki, Othman Nashwa, Mahmoud Tarek, Nair Parasad, A-Halim Medhat, Jahrami Kawthar, Gheith Osama
Аннотация
OBJECTIVES: Posttransplant diabetes mellitus is a chronic metabolic complication that often develops in kidney transplant recipients and is an inflammatory disease that directly affects a patient's immune system. Angiopoietin and angiopoietin -like proteins are intrinsic mediators of immune cells. We assessed the relationship between circulating angiopoietin proteins ANGPT ¹ and ANGPT ²and angiopoietin-like proteins ANGPTL ³, ANGPTL ⁴, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸ in kidney transplant recipients who develop posttransplant diabetes mellitus (experimental group) versus recipients who do not develop diabetes after transplant (control group).
MATERIALS AND METHODS: We included 154 age-matched and sex-matched participants (38 with posttransplant diabetes mellitus) and 155 control participants. We collected 3 mL of venous blood from each patient. Plasma levels of angiopoietin proteins ANGPT ¹ and ANGPT ² and angiopoietin-like proteins ANGPTL ³, ANGPTL ⁴, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸ were determined by enzyme-linked immunosorbent assay. We determined the correlation between plasma levels of ANGPT ¹and ANGPT ² and ANGPTL ³, ANGPTL ⁴, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸in our posttransplant diabetes mellitus group and the control group.
RESULTS: There were highly significant differences between kidney transplant recipients with diabetes versus control participants with regard to plasma levels of ANGPT ¹, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸ (P < . ⁰⁰¹, P = . ⁰⁰¹, P < . ⁰⁰¹, and P =.⁰⁴, respectively). No significant statistical association was found for ANGPT2, ANGPTL3, and ANGPTL4 in our posttransplant diabetes mellitus cohorts.
CONCLUSIONS: Plasma levels of ANGPT¹, ANGPTL⁶, ANGPTL⁷, and ANGPTL ⁸ may correlate with disease severity and chronicity in transplant patients who develop posttransplant diabetes mellitus. Thereby these may serve as potential biomarkers of the disease severity with possible early intervention in the management strategy especially with modifiable risk factors such as immunosuppression regimen, antidiabetic medications, and follow-up of the complications of posttransplant diabetes mellitus.
MATERIALS AND METHODS: We included 154 age-matched and sex-matched participants (38 with posttransplant diabetes mellitus) and 155 control participants. We collected 3 mL of venous blood from each patient. Plasma levels of angiopoietin proteins ANGPT ¹ and ANGPT ² and angiopoietin-like proteins ANGPTL ³, ANGPTL ⁴, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸ were determined by enzyme-linked immunosorbent assay. We determined the correlation between plasma levels of ANGPT ¹and ANGPT ² and ANGPTL ³, ANGPTL ⁴, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸in our posttransplant diabetes mellitus group and the control group.
RESULTS: There were highly significant differences between kidney transplant recipients with diabetes versus control participants with regard to plasma levels of ANGPT ¹, ANGPTL ⁶, ANGPTL ⁷, and ANGPTL ⁸ (P < . ⁰⁰¹, P = . ⁰⁰¹, P < . ⁰⁰¹, and P =.⁰⁴, respectively). No significant statistical association was found for ANGPT2, ANGPTL3, and ANGPTL4 in our posttransplant diabetes mellitus cohorts.
CONCLUSIONS: Plasma levels of ANGPT¹, ANGPTL⁶, ANGPTL⁷, and ANGPTL ⁸ may correlate with disease severity and chronicity in transplant patients who develop posttransplant diabetes mellitus. Thereby these may serve as potential biomarkers of the disease severity with possible early intervention in the management strategy especially with modifiable risk factors such as immunosuppression regimen, antidiabetic medications, and follow-up of the complications of posttransplant diabetes mellitus.